Correlation Between Circulating Biomarkers of Organs Damage and Intraoperative Hypotension Management

NCT ID: NCT03527758

Last Updated: 2020-04-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-11-01

Study Completion Date

2020-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intraoperative hypotension (defined as mean arterial pressure below 65 mmHg) is associated with increased organs dysfunction and mortality. Even short durations of reduced arterial blood pressure episodes significantly increased the risk of myocardial injury, neurological deficits, renal failure, and mortality. Hypotension rate during surgery is quite common and recent studies showed an incidence up to 60% of patients endured hypotension during anesthesia for an average of 10% of surgical time.

Nowadays hypotension seems to be preventable even if current management of the hypotensive episodes is predominantly reactive and rather occurs with some delay.

The investigators hypothesize that the prevention of hypotension by means Edwards Lifesciences new technology (HPI software) can improve patients outcome after surgery.

The present pilot randomized clinical trial is aimed at investigating various biomarkers involved in organ dysfunction and how they correlate with different intraoperative hypotension management strategies (Invasive blood pressure monitored by a normal arterial line vs Invasive blood pressure monitored by Edwards FloTracIQ system with HPI software).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this pilot study is to investigate if an early treatment of intraoperative hypotension driven by an Edwards Lifesciences new technology (Hypotension Probability Index - HPI software) and integrated hemodynamic variables is able to determine a modification of the blood levels of several specific biomarkers of tissue and organ damage compared to a traditional management of hypotension. It will also be evaluated if the management strategy of patient hemodynamics based on the Hypotension Probability Index (HPI) is associated with a lower incidence of hypotensive events and / or a shorter overall duration of intraoperative hypotension.

In the study will be enrolled forty adult patients requiring an arterial line (at discretion of treating physician) undergoing non-cardiac non-day surgery (with an expected duration of more than 2 hours and an aimed medium arterial pressure - MAP of 65 mmHg) at the Universitary Hospital of Catania.

The patients will be randomly (1:1) assigned to one of the subsequent two groups: a group monitored with FloTracIQ with HPI software (Treatment Group) and a group with standard invasive blood pressure monitoring (Control Group).

In the Control Group, all hypotensive episodes during surgery will be treated according to standard of care.

Patients randomized to the Treatment Group will receive monitoring with integration of HPI index and hemodynamic parameters visible on the EV1000 platform; these informations will be used to guide the investigator in the choice of the more appropriate treatment to be carried out. The value of HPI is updated every 20 seconds and expresses in percentage the probability of occurrence of a hypotensive event. The cut-off value of HPI is equal to 85%. Values above the cut-off are related to a higher probability of hypotension. A specific visual and sound "ALERT" will indicate to the investigator if the threshold value is reached / exceeded. Any treatment strategy will be based on integrated analysis of clinical and instrumental data showed on the screen of the EV1000 platform \[MAP, cardiac output (CO), systemic vascular resistance (SVR), stroke volume (SV), stroke volume variation (SVV), intra-ventricular pressure rate of rise (dP/dt), dynamic arterial elastance (Eadyn)\].

In both groups different blood samplings will be performed in order to assess biomarkers of specific organ dysfunction: T0 (baseline, before starting operating procedures); T1 (2 hours after starting anesthesia); T2 (at the end of surgical procedures). The following biomarkers will be assessed: neuron specific enolase and S100B (for brain monitoring); high sensitive cardiac troponin T (for heart monitoring); Neutrophil Gelatinase-Associated Lipocalin (NGAL, for kidney monitoring); circulating endothelial cells counting and cytofluorimetric analysis (for endothelial monitoring). There will also be determined the systemic effect of intraoperative hypotension as measured by inflammatory cytokines \[Interleukin (IL)-6, IL-1 beta and Tumor necrosis factor (TNF)-alfa\], oxidative stress (reduced glutathione, lipid hydroperoxides) and markers of hypoxia (HIF1alpha, lactate, acetylCoA, CoA).

Various clinical informations will be collected at the same time: glomerular filtration rate, plasma electrolytes, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood gasses analysis, anion gap.

A telephone interview will be performed one month after surgery, in order to investigate general health condition and any re-admission to hospital.

Sample size calculation:

Given the pilot nature of the study, no formal justification of sample size has been made.

Statistical analysis:

For a test of normal distribution, the Kolmogorov-Smirnov test will be used. Continuous data with normal distribution will be tested with paired or unpaired t tests, non-normally distributed data using Mann-Whitney U test and Wilcoxon rank-sum test for unpaired and paired results, respectively.

Changes in biomarkers over time will be tested using analysis of variance (ANOVA) on repeated measurements. Categorical data will be tested using Chi-square test and Chi-square test for trend. Data will be presented as mean ± standard deviation when normally distributed and as median \[interquartile ranges\] in case of abnormal distribution. A p \< 0.05 will be considered statistically significant for all tests.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypotension Brain Injuries Renal Failure Endothelial Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Invasive intraoperative monitoring

Group Type NO_INTERVENTION

No interventions assigned to this group

Flo TracIQ with HPI software

Group Type EXPERIMENTAL

Flo TracIQ with HPI software

Intervention Type DEVICE

Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flo TracIQ with HPI software

Patients will be monitored intraoperatively with Flo TracIQ with HPI software in order to predict hypotensive events. Blood sample will be obtained in order to evaluate ealy organ dysfunction.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 years or older;
* Planned for elective non-cardiac non-day surgery with an expected duration of more than 2 hours;
* Planned to receive general anesthesia;
* Planned to receive an arterial line during surgery;
* Aim for MAP of 65 mmHg during surgery;
* Being able to give written informed consent prior to surgery.

Exclusion Criteria

Age less than 18 years;

* Aim for MAP other than 65 mmHg at discretion treating physician;
* Significant hypotension before surgery defined as a MAP \<65;
* Right- or left sided cardiac failure \[e.g. left ventricular ejection fraction (LVEF)\<35%\];
* Known cardiac shunts (significant);
* Known aortic stenosis (severe);
* Severe cardiac arrhythmias including atrial fibrillation;
* Chronic kidney disease (as chronic kidney disease may affect the interpretation and prognostic significance of changes in urinary biomarkers);
* Liver surgery;
* Vascular surgery with clamping of the aorta;
* Diabetes.
Minimum Eligible Age

21 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Giovanni Li Volti

UNKNOWN

Sponsor Role collaborator

Marinella Astuto

UNKNOWN

Sponsor Role collaborator

Francesco Vasile

UNKNOWN

Sponsor Role collaborator

Gaetano Joseph Palumbo

UNKNOWN

Sponsor Role collaborator

Mirko Mineri

UNKNOWN

Sponsor Role collaborator

Christian Bonsignore

UNKNOWN

Sponsor Role collaborator

Salvatore Pennisi

UNKNOWN

Sponsor Role collaborator

Carmelo Minardi

UNKNOWN

Sponsor Role collaborator

Bruno Lanzafame

UNKNOWN

Sponsor Role collaborator

Luigi Lavia

UNKNOWN

Sponsor Role collaborator

Veronica Dezio

UNKNOWN

Sponsor Role collaborator

University of Catania

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Paolo Murabito

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

"G. Rodolico" Presidium of the Azienda Ospedaliero Universitaria "Policlinico-Vittorio Emanuele"

Catania, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

46/2018/PO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Parameters of Cerebral Perfusion
NCT02806492 COMPLETED NA
Biomarkers Correlation With Volemia
NCT01858675 COMPLETED NA